Overview
- Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi joined earlier signers, bringing participation to 14 of the 17 manufacturers the White House targeted in July.
- The framework commits companies to most-favored-nation pricing for state Medicaid programs and to sell selected medicines directly to consumers through manufacturer portals that will be centralized by TrumpRx.gov, expected to go live in January 2026.
- The White House and companies cited specific direct-purchase price examples, including Gilead’s Epclusa from $24,920 to $2,425, Sanofi insulin at $35 per month, Merck’s Januvia from $330 to $100, and Sanofi’s Plavix from $756 to $16.
- Participating firms pledged roughly $150 billion in U.S. manufacturing and R&D investment and agreed to donate active pharmaceutical ingredients to a strategic reserve, while receiving a three-year exemption from potential tariffs.
- Health policy experts questioned how much most insured Americans will save given existing coverage rules and Medicaid’s already steep discounts, and three major companies—AbbVie, Johnson & Johnson and Regeneron—have not finalized agreements.